^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

SO-32 Biomarker analysis of the phase III IMblaze370 trial of atezolizumab plus cobimetinib or atezolizumab monotherapy vs regorafenib in third-line CRC

Published date:
07/08/2020
Excerpt:
Atezolizumab + cobimetinib showed benefit over regorafenib in patients with certain low prevalence tumor subsets, such as those with a PI3K/Akt mutation or WNT pathway wild-type tumors.
DOI:
https://doi.org/10.1016/j.annonc.2020.04.047